NGS technology has been embraced globally, with leading oncology guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) recommending its use in the evaluation of advanced NSCLC prior to the initiation of treatment. The rationale is clear: uncovering actionable mutations—those amenable to targeted therapies—is critical for personalizing treatment and improving patient outcomes. Traditionally, tissue biopsy remains the gold standard for obtaining tumor DNA, but this method is not without significant limitations.

A striking challenge noted in clinical practice is the inadequacy of tissue samples; up to 20% of biopsies fail to provide sufficient material for comprehensive molecular testing covering all nine FDA-approved biomarkers relevant to NSCLC. This limitation restricts the ability to identify key driver mutations that dictate targeted therapy suitability, potentially leaving patients without optimal treatment options.

Currently, clinical guidelines advocate for plasma-based NGS primarily as a secondary option, recommended when tissue samples are insufficient or unattainable. Plasma-based NGS analyzes circulating tumor DNA (ctDNA) in the bloodstream, offering a minimally invasive alternative to biopsy. Although promising, its role has been conventionally viewed as supplementary rather than primary.

The retrospective cohort study at the core of this new research challenges this paradigm by focusing on 43 patients who underwent both tissue and first-line plasma-based NGS. Within this group, 22 were of Asian descent, a demographic known to harbor a distinct molecular profile in NSCLC. Remarkably, half of these Asian patients exhibited actionable mutations, with an overwhelming 81.8% of these involving epidermal growth factor receptor (EGFR) mutations—mutations that are pivotal for targeted therapy decisions in NSCLC.

One of the most compelling revelations from the study is that plasma-based NGS detected all EGFR mutations identified by tissue biopsy and additionally uncovered two mutations that tissue testing missed entirely. This finding alone signals a potential paradigm shift: relying purely on tissue biopsy could result in missing over 22% of actionable EGFR mutations that plasma NGS could detect upfront.

The implications of these findings are profound, especially considering the statistical significance of mutation detection disparities across ethnic and lifestyle factors. The study found that Asian patients are significantly more likely to harbor EGFR mutations compared to White patients, with a p-value of 0.004. Similarly, nonsmokers have a higher mutation detection rate than smokers, supported by a p-value of 0.017. These robust statistical markers affirm the necessity to tailor diagnostic strategies by factoring in ethnicity and smoking status.

What is particularly intriguing is the subset of patients who displayed actionable EGFR mutations exclusively on plasma-based NGS, despite having sufficient tissue available for traditional testing. This paradox highlights a limitation of tissue NGS, possibly stemming from tumor heterogeneity or sampling bias where a single biopsy may not capture the full genetic complexity of a tumor.

These patients who were identified uniquely by plasma NGS benefited from targeted therapies to varying degrees, which reinforces the clinical utility of plasma-based testing. This clinical benefit stresses the importance of integrating plasma NGS into frontline diagnostics rather than reserving it solely as a fallback method when tissue is unavailable.

Given the meticulous analysis and compelling evidence presented, the study advocates for a revised diagnostic approach. It suggests considering plasma-based NGS in the initial diagnostic phase, especially for Asian patients and nonsmokers, even when tissue biopsy is adequate for molecular profiling. This strategy could accelerate the identification of actionable mutations, thereby expediting the timely initiation of personalized therapies.

Furthermore, plasma-based NGS offers the advantage of being less invasive, reducing procedure-associated risks and patient discomfort. It also facilitates serial monitoring of tumor genomics during treatment, offering a dynamic window into tumor evolution and resistance mechanisms that tissue biopsies cannot easily provide.

This study thereby adds a vital piece of evidence advocating for the harmonization of tissue and plasma-based methodologies, leveraging their complementary strengths to optimize mutation detection and therapeutic alignment in NSCLC.

As precision oncology continues to progress, the integration of plasma-based NGS as part of first-line diagnostic algorithms marks a notable stride toward truly personalized cancer care. With technologies becoming more sensitive and cost-effective, plasma NGS could soon overhaul current practices, especially in populations with high prevalence of specific genetic drivers like the Asian community studied here.

The future of lung cancer diagnosis and treatment beckons a hybrid approach where plasma-based NGS is not an afterthought but a front-running contender to unlock critical molecular insights early in the care pathway.

In summary, the findings accentuate the need for clinicians to broaden their toolkit in molecular diagnostics by incorporating plasma-based NGS to enhance mutation detection rates. This approach promises to minimize missed opportunities for targeted therapies, particularly for patients who traditionally face challenges due to tissue sample limitations or unique genetic backgrounds.

As research advances, it becomes increasingly clear that empowering clinicians with comprehensive diagnostic tools will usher an era of highly individualized medicine, ultimately translating into better survival and quality of life for patients with advanced NSCLC.

The study’s revelations illuminate the transformative potential lying within liquid biopsies and encourage a reevaluation of current guidelines to embrace plasma-based NGS as a vital frontline diagnostic modality.

Subject of Research: Evaluation of plasma-based next generation sequencing in detection of actionable mutations in advanced non-small cell lung cancer, with a focus on Asian patients.

Article Title: Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients

Article References:
Wu, CH., Wu, X., Hu, X. et al. Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15295-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15295-2

Non-small cell lung cancer remains a leading cause of cancer-related mortality worldwide, with pleural dissemination representing a critical prognostic factor. Occult PD, referring to pleural metastasis not visible through standard imaging, poses a unique challenge. Traditional CT scans, while foundational in lung cancer assessment, frequently fail to reveal these subtle disease manifestations. Consequently, patients may undergo radical surgery, only to discover postoperative that the cancer had spread, diminishing the surgery’s therapeutic value and patient survival. Accurate, non-invasive preoperative identification of occult PD is therefore imperative.

To tackle this clinical conundrum, the research team retrospectively collected CT images from 326 NSCLC patients treated across three high-volume medical centers in China from 2016 to 2023. This multicenter approach enhanced the study’s robustness, offering a diverse and representative patient cohort. The dataset was split into training, internal test, and external test subsets, facilitating comprehensive evaluation of model generalizability. Each patient’s CT scan was focused at the maximum cross-sectional slice of the primary tumor — a strategy designed to capture critical tumor features while maintaining computational tractability.

The researchers deployed ten radiomics-based machine learning (ML) models alongside eight deep learning (DL) architectures, each designed to extrapolate meaningful patterns from the intricate imaging data. Radiomics involves the extraction of high-dimensional quantitative features from medical images—such as texture, shape, and intensity—that are imperceptible to the human eye but statistically linked to clinical outcomes. In contrast, deep learning models leverage hierarchical neural networks, such as DenseNet121, to autonomously learn discriminative imaging characteristics directly from pixel data, representing a paradigm shift towards end-to-end learning.

Fascinatingly, the study did not stop at comparing ML and DL models in isolation; it introduced two sophisticated fusion models. The prefusion model integrated feature-based data from ML and DL, aiming to combine the strengths of engineered and learned representations. Alternatively, the postfusion model merged the decision outputs—the predictive probabilities—from the best-performing ML and DL networks, specifically gradient boosting machines (GBM) and DenseNet121. This decision-level fusion hypothesized to capitalize on complementary predictive insights and boost diagnostic accuracy.

Performance evaluation was anchored in receiver operating characteristic (ROC) curve analysis, with the area under the curve (AUC) serving as the principal metric. In the external test cohort, the GBM model led machine learning approaches with an AUC of 0.821, affirming its strong discriminative power. Meanwhile, DenseNet121 emerged as the top deep learning model, achieving a respectable AUC of 0.764. These baseline benchmarks underscored the efficacy of both methodologies, yet also highlighted potential limitations when applied independently.

The postfusion model surpassed expectations, showcasing AUC ranges between 0.828 and an extraordinary 0.978 across all cohorts. This leap in performance validates the hypothesis that integrating the probabilistic outputs from distinct analytical frameworks enhances overall model sensitivity and specificity. Notably, the postfusion model demonstrated sensitivity rates soaring from 82.1% to 97.2%, critical for reducing false negatives in clinical practice. Such sensitivity is invaluable in ensuring patients with undetected pleural metastasis are identified accurately, thereby avoiding futile surgery.

These findings carry profound clinical significance. By accurately predicting occult PD, the fusion model equips clinicians with a non-invasive, highly sensitive tool to better stratify NSCLC patients prior to surgery. This personalized approach can prevent unnecessary invasive interventions, optimize treatment timelines, and improve patient quality of life. Moreover, it embodies the future of precision oncology, integrating multidisciplinary data analytics with everyday imaging technologies.

From a technical perspective, the study navigates complex challenges intrinsic to medical AI research. The use of multicenter data addresses variability in imaging protocols and patient demographics, tackling the notorious issue of model overfitting and ensuring generalizability. The comparison between handcrafted radiomic features and deep learning models also provides valuable insights into complementary strengths, informing ongoing debates about the best AI strategies in radiology.

The use of gradient boosting machines in radiomics highlights the continuing relevance of ensemble ML techniques in analyzing structured data, while DenseNet121 exemplifies modern convolutional neural network architectures optimized for feature reuse and gradient flow, mitigating common issues like vanishing gradients and network degradation. The decision-based fusion approach, effectively combining model outputs, represents an elegant solution akin to ensemble learning, but at the probability level, maximizing consensus and reducing individual biases.

Beyond NSCLC and pleural dissemination, this research signals broader implications for oncologic imaging. The integration of radiomics and deep learning may extend to other cancers and modalities, spearheading a wave of AI tools tailored to detect subtle metastatic disease that evade human visual detection. This synergy between algorithmic precision and imaging richness promises to enhance early detection, treatment planning, and prognostic assessment across oncology.

Nevertheless, challenges remain before widespread clinical adoption. The computational demands and interpretability of combined models can pose barriers to routine use. Regulatory approval pathways must evolve to accommodate AI fusion models, ensuring safety and efficacy. Additionally, prospective validation and real-world implementation studies are essential to confirm these promising retrospective results.

This landmark study represents a milestone in the journey toward smarter, more sensitive cancer diagnostics. By showcasing how the fusion of radiomics and deep learning outperforms either method alone, it opens new horizons for personalized medicine. As AI continues to revolutionize medical imaging, the potential to change patient trajectories and health outcomes has never been greater.

For clinicians and researchers alike, these insights invite a reevaluation of diagnostic workflows, encouraging the integration of hybrid AI models. The fusion strategy articulated here provides a blueprint for future algorithm development, balancing complexity, accuracy, and clinical utility. Ultimately, such innovations stand to transform lung cancer management and affirm the transformative role of artificial intelligence in medicine.

As the medical community pushes forward, studies like this reinforce the critical importance of multidisciplinary collaboration—uniting radiologists, oncologists, data scientists, and engineers. Together, they are crafting tools that not only detect disease but also anticipate patient needs, enabling truly personalized therapeutic strategies. This research embodies the promise and power of AI to enhance human decision-making in the fight against cancer.

The research team led by Bao, Li, Deng, and colleagues should be applauded for this essential contribution to precision oncology. Their meticulous methodology, thoughtful model architecture design, and rigorous validation represent a model of scientific excellence. The findings, published in BMC Cancer, mark a pivotal step in the quest to outsmart cancer’s hidden advances and offer hope to thousands of NSCLC patients worldwide.

Subject of Research: Predictive modeling of occult pleural dissemination in non-small cell lung cancer patients using radiomics, deep learning, and fusion AI models.

Article Title: Comparing radiomics, deep learning, and fusion models for predicting occult pleural dissemination in patients with non-small cell lung cancer: a retrospective multicenter study.

Article References: Bao, T., Li, X., Deng, Y. et al. Comparing radiomics, deep learning, and fusion models for predicting occult pleural dissemination in patients with non-small cell lung cancer: a retrospective multicenter study. BMC Cancer 25, 1670 (2025). https://doi.org/10.1186/s12885-025-15121-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15121-9